Telo GenomicsTDSGF 3-Year ROIIC % is 2,192.59 as of Jun. 2025, which is 760% above its 10-year median of 255.07. The stock has 2 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Telo Genomics ranks better than 96.55% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Telo Genomics's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 2,192.59%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Telo Genomics's 3-Year ROIIC % or its related term are showing as below:
TDSGF's 3-Year ROIIC % is ranked better than 96.55% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22
vs TDSGF: 2192.59
Telo Genomics (OTCPK:TDSGF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Telo Genomics 3-Year ROIIC % Related Terms
Telo Genomics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Telo Genomics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TDSGF vs TMO, DHR, IDXX: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Telo Genomics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telo Genomics 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Telo Genomics's 3-Year ROIIC % falls into.
Telo Genomics's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -1.977 (Jun. 2025) - -1.648 (Jun. 2022) )
/
( 0.014 (Jun. 2025) - 0.036 (Jun. 2022) )
=
-0.329
/
-0.022
=
1,495.45%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Telo Genomics (TDSGF) has a 3-Year ROIIC % of 2,192.59 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Telo Genomics and its competitors. This is 760% above median its historical median of 255.07. According to the industry distribution chart, Telo Genomics ranks #7 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 3.4%.
Is Telo Genomics' 3-Year ROIIC % too high?
Telo Genomics' current 3-Year ROIIC % of 2,192.59 is 760% above median its 10-year median of 255.07. The Medical Diagnostics & Research industry median 3-Year ROIIC % is 0.22. Telo Genomics' value of 2,192.59 is 996531.8% above this industry median. Based on the distribution chart, Telo Genomics ranks #7 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Telo Genomics' 3-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Telo Genomics ranks #7 out of 203 companies for 3-Year ROIIC %. This places Telo Genomics in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 0.22. Telo Genomics' value of 2,192.59 is 996531.8% above this benchmark. While the company's 10-year median is 255.07 vs. the industry median of 0.22, Telo Genomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.22, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telo Genomics's current 3-Year ROIIC % of 2,192.59 is 996531.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Telo Genomics and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telo Genomics's current 3-Year ROIIC % is 2,192.59, which is 760% above median its own 10-year median of 255.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telo Genomics stock overvalued right now?
Telo Genomics (TDSGF) has a current 3-Year ROIIC % of 2,192.59. The current 3-Year ROIIC % is 2,192.59, which is 760% above median its 10-year median of 255.07 and 996531.8% above the Medical Diagnostics & Research industry median of 0.22. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Telo Genomics (TDSGF), the current 3-Year ROIIC % is 2,192.59 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TDSGF has been successfully added to your 